Day One Announces Updated FIREFLY-1 Data for Tovorafenib
Overall response rate (ORR) greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023,...
Source: globenewswire.com
Demonstrate Consistent News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Demonstrate Consistent. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Demonstrate Consistent Today - Breaking & Trending Today
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)
Overall response rate greater than 50% across three assessment criteria Median duration of tovorafenib treatment of 15.8 months as of June 5, 2023, with 66% of patients remaining on treatment FDA...
Source: marketscreener.com